337. Homocystinuria Clinical trials / Disease details
Clinical trials : 16 / Drugs : 19 - (DrugBank : 7) / Drug target genes : 2 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05462132 (ClinicalTrials.gov) | July 7, 2022 | 7/7/2022 | Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers | A Phase 1, Dose-escalation, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1353 in Healthy Volunteers | Homocystinuria | Drug: SYNB1353 | Synlogic | NULL | Completed | 18 Years | 64 Years | All | 31 | Phase 1 | United States |